Phase 1 expansion study of non-coding RNA-based candidate CV8102 confirms safety and strong immuno-modulatory characteristics First manufacturing licenses for The RNA Printer® in oncology expected, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results